Showing 1 - 20 results of 23 for search '"хроническая воспалительная демиелинизирующая полиневропатия"', query time: 0.68s Refine Results
  1. 1
  2. 2
  3. 3
    Academic Journal

    Source: Neuromuscular Diseases; Том 11, № 1 (2021); 39-46 ; Нервно-мышечные болезни; Том 11, № 1 (2021); 39-46 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2021-11-1

    File Description: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/425/287; Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst 2010;15:1–9. DOI:10.1111/j.1468-1331.2009.02930.x. PMID: 20456730.; Mathey E.K., Park S.B., Hughes R.A.C. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015;86:973–85. DOI:10.1136/jnnp-2014-309697. PMID: 25677463.; Ryan R., Ryan S.J. Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. Am J Manag Care 2018;24:S371–9. PMID: 30312032.; Rodríguez Y., Vatti N., RamírezSantana C. et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmunity 2019;102:8–37. DOI:10.1016/j. jaut.2019.04.021. PMID: 31072742.; Chiò A., Cocito D., Bottacchi E. et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007;78:1349–53. DOI:10.1136/jnnp.2007.114868. PMID: 17494979.; Laughlin R.S., Dyck P.J., Melton L.D. et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73(1):39–4.DOI:10.1212/WNL.0b013e3181aaea47. PMID: 19564582.; Rajabally Y.A., Simpson B.S., Beri S. et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009;39(4):432–8. DOI:10.1002/mus.21206. PMID: 19260065.; Lewis R.A. Chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 2017;30(5):508–12. DOI:10.1097/WCO.0000000000000481. PMID: 28763304.; Попова Т.Е., Шнайдер Н.А., Петрова М.М. и др. Эпидемиология хронической воспалительной демиелинизирующей полиневропатии за рубежом и в России. Нервно-мышечные болезни 2015;5(2):10–5. [Popova T.E., Shnayder N.A., Petrova M.M. et al. Epidemiology of chronic inflammatory demyelinating polyneuropathy abroad and in Russia. Nervno-myshechnye bolezni = Neuromuscular Diseases 2015;5(2):10–5. (In Russ.)]. DOI:10.17650/2222-87212015-5-2-10-15.; Кантимирова Е.А., Шнайдер Н.А. Хроническая воспалительная демиелинизирующая полинейропатия: дефиниция, эпидемиология, классификация, диагностика. Вестник клинической больницы № 51 2009;(7):22–5. [Kantimirova E.A., Sknayder N.A. Chronic inflammatory demyelinating polyneuropathy: definition, epidemiology, classification, diagnosis. Vectnik Klinicheskoy Bolnitsy № 51 = Clinical Hospital Bulletin No. 51 2009;(7):22–5. (In Russ.)]. DOI: 10.17.650/2222-87212016-6-1-44-53.; Van den Berg B., Walgaard C., Drenthen J. et al. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10(8):469–82. DOI:10.1038/nrneurol.2014.121. PMID: 25023340.; Hughes R.A.C., Rees J.H. Clinical and epidemiologic features of Guillain–Barré syndrome. J Infect Dis 1997;176(Suppl 2): S92–8. DOI:10.1086/513793. PMID: 9396689.; Willison H.J., Goodyear C.S. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol 2013;34:453–9. DOI:10.1016/j. it.2013.05.001. PMID: 23770405.; Wakerley B.R., Yuki N. Infectious and noninfectious triggers in Guillain-Barre syndrome. Expert Rev Clin Immunol. 2013;9(7):627–39. DOI:10.1586/1744666 X.2013.811119 ome. PMID: 23899233.; Lehmann H.C., Hughes R.A., Kieseier B.C., Hartung H.P. Recent developments and future directions in Guillain–Barré syndrome. J Peripher Nerv Syst 2012;17:57–70. DOI:10.1111/j.1529-8027.2012.00433.x. PMID: 23279434.; Sejvar J.J., Baughman A. L., Wise M., Morgan O.W. Population incidence of Guillain–Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123–33. DOI:10.1159/000324710. PMID: 21422765.; Webb A.J., Brain S.A., Wood R. et al. Seasonal variation in Guillain-Barré syndrome: a systematic review, metaanalysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry 2015;86:1196–201. DOI:10.1136/jnnp-2014-309056. PMID: 25540247.; Chiò A., Cocito D., Leone M. et al. Register for Guillain–Barré syndrome: A prospective, population-based incidence and outcome survey. Neurology 2003;60:1146–50. DOI:10.1212/01.wnl.0000055091.96905.d0. PMID:12682322.; Matsui N., Nodera H., Kuzume D. et al. Guillain–Barr syndrome in a local area in Japan, 2006–2015: an epidemiological and clinical study of 108 patients. Eur J Neurol 2018;25(5):718–24. DOI:10.1111/ene.13569. PMID: 29337417.; Huang W.C., Lu C.L., Chen S.C. A 15-year nationwide epidemiological analysis of Guillain–Barré syndrome in Taiwan. Neuroepidemiology 2015;44(4):249–54. DOI:10.1159/000430917. PMID: 26088600.; Супонева Н.А., Пирадов М.А., Гнедовская Е.В. Синдром Гийена–Барре в городах Российской Федерации: эпидемиология, диагностические и терапевтические возможности региональных клиник. Здравоохранение Российской Федерации 2013;(1):19–25. [Suponeva N.A., Piradov M.A., Gnedovskaya E.V. Guillain–Barré syndrome in the cities of the Russian Federation: epidemiology, diagnostic and therapeutic capabilities of regional clinics. Zdrovookhranenie Rossiyskoy Federatsii = Healthcare of the Russian Federation 2013;(1):19–25. (In Russ.)].; Dyck P.J.B., Tracy J.A. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc 2018;93(6):777–93. DOI:10.1016/j.mayocp.2018.03.026. PMID: 29866282.; Hadden R.D., Cornblath D.R., Hughes R.A. et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 1998;44(5):780–8. DOI:10.1002/ana.410440512. PMID: 9818934.; Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: диагностика и лечение. М.: МЕДпресс, 2011. 208 с. [Piradov M.A., Suponeva N.A. Guillain–Barré syndrome: diagnosis and treatment. Moscow: MEDpress, 2011. 208 p. (In Russ.)].; Синдром Гийена–Барре. Клинические рекомендации. Под общ. ред. М.А. Пирадова, Н.А. Супоневой, Д.А. Гришиной. М.: Горячая линия – Телеком, 2018. 32 с. [Guillain–Barré syndrome. Clinical guidelines. Eds.: M.A. Piradov, N.A. Suponeva, D.A. Grishina. Moscow: Goryachaya Liniya – Telekom, 2018. 32 p. (In Russ.)]. DOI:10.25780/0001.; Tarkowski S. Human ecology and public health. Eur J Public Health 2009;19(5):447.10.1093. DOI:10.1093/ eurpub/ckp152. PMID: 19770227.; McLeod J.G., Pollard J.D., Macaskill P. et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 2001;46(6):910–13. DOI:10.1002/1531-8249(199912)46:63.0.CO; 2-2. PMID: 10589544.; Stojanovich L., Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev 2008;7(3):209–13. DOI:10.1016/j.autrev.2007.11.007. PMID: 18190880.; Okada H., Kuhn С., Feillet H., Bach J.-F. The “hygiene hypothesis” for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010;160(1):1–9. DOI:10.1111/j.1365-2249.2010.04139.x. PMID: 20415844.; Чижевский А.Л. Земное эхо солнечных бурь. М.: Мысль, 1976. 367 с. [Chizhevskiy A.L. Earthly echo of solar storms. Moscow: Mysl, 1976. 367 p. (In Russ.)].; José L.A., Pastor Rueda. M., Wilken M. et al. Differences between acute – onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J Periph Nerv Sys 2018;23(3): 151–206. DOI:10.1111/jns.12266.; Супонева Н.А., Мочалова Е.Г., Гришина Д.А., Пирадов М.А. Особенности течения СГБ в России: анализ 186 случаев. Нервно-мышечные болезни 2014;(1):37–46. [Suponeva N.A., Mochalova E.G., Grishina D.A., Piradov M.A. Features of the course of GBS in Russia: analysis of 186 cases. Nervno-myshechnye bolezni = Neuromuscular Diseases 2014;(1):37–46. (In Russ.)]. DOI:10.17650/2222-8721-2014-0-1-40-47.; Возрастно-половой состав населения Ленинградской области на 1 января 2018 г. Статистический бюллетень. Санкт-Петербург, 2018. [Age and sex composition of the population of the Leningrad Region as of January 1, 2018. Statistical Bulletin. Saint Petersburg, 2018. (In Russ.)].; World Health Organization. European Health Informational Gateway. Available at: https://gateway.euro.who.int/en/.; https://nmb.abvpress.ru/jour/article/view/425

  4. 4
  5. 5
    Academic Journal

    Source: Neuromuscular Diseases; Том 5, № 4 (2015); 16-23 ; Нервно-мышечные болезни; Том 5, № 4 (2015); 16-23 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2015-5-4

    File Description: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/128/123; Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: диагностика и лечение. Руководство для врачей. М.: МЕДпресс-информ, 2011. 200 с. [Piradov M.A., Suponeva N.A. The Guillain–Barré syndrome: diagnosis and treatment. A guide for physicians. Moscow: MEDpress-inform, 2011. 200 p. (In Russ.)].; Gilhus N.E., Barnes M.P., Brainin M. Multi focal Motor Neuropathy, in European Handbook of Neurological Management. Wiley-Blackwell, Oxford, UK, 2010. 2nd еd. Vol. 1, ch. 21.; Elovaaraa S., Apostolskib P., van Doorn et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893–908.; Van der Meché F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain- Barré Study Group. N Engl J Med 1992;326(17):1123–9.; Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Plasma Exchange/Sandoglobulin Guillain– Barré Syndrome Trial Group. Lancet 1997;349(9047):225–30.; Van Schaik I.N., Winer J.B., de Haan R., Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;2.; Супонева Н.А., Пирадов М.А., Гнедовская Е.В. Качество медицинской помощи больным с синдромом Гийена–Барре в России. Материалы первой учредительной конференции РОО «Общество специалистов по нервно-мышечным болезням» «Актуальные вопросы диагностики и лечения нервно-мышечных болезней». 2012. С. 41. [Suponeva N.A., Piradov M.A., Gnedovskay E.V. Quality medical care for patients with Guillain–Barre syndrome in Russia. Proceedings of the first inaugural conference of the NGO “Society of neuromuscular diseases” “Topical issues of diagnosis and treatment of neuromuscular diseases”. 2012. S.41. (In Russ.)].; Teschner W., Butterweck H.A., Auer W. et al. A new liquid, intravenous immunoglobulin product (IGIV 10 %) highly purified by a stateof- the-art process. Vox Sang. 2007;92(1):42–55.; Lebing W., Remington K.M., Schreiner C., Paul H.I. Properties of a new intravenous immunoglobulin (IGIV-C, 10 %) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003;84(3):193–201.; Donofrio P.D., Bril V., Dalakas M.C. et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. IGIV-C CIDP Efficacy (ICE) Study Group. Arch Neurol 2010;67:1082–8.; Kuitwaard K., van der Berg L.H., Vermeulen M. et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010;81:1374–9.; Schiff R.I., Williams L.W., Nelson R.P. et al. Multi-centre crossover comparison of safety and efficacy of Intraglobin-F with Gamimune- N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997;17:21–8.; Dantal J. Intravenous Immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38:275–84.; Супонева Н.А., Пирадов М.А. Внутривенная иммунотерапия в неврологии. М.: Горячая линия телеком, 2013. 320 с. [Suponeva N.A., Piradov M.A. Intravenous immunotherapy in neurology. Moscow: Hot Line Telecom, 2013. 320 p. (In Russ.)].; Lenk C., Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 2014;10:537–46.; https://nmb.abvpress.ru/jour/article/view/128

  6. 6
    Academic Journal

    Source: Neuromuscular Diseases; № 4 (2012); 59-65 ; Нервно-мышечные болезни; № 4 (2012); 59-65 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2012-0-4

    File Description: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/100/96; Куренков А.Л., Никитин С.С., Бурсагова Б.И., Кузенкова Л.М. Особенности хронической воспалительной демиелинизирующей полинейропатии у детей. Нервно-мышечные болезни 2012;2:40–51.; Аверочкин А.И., Мозолевский Ю.В., Штульман Д.Р. Заболевания периферической нервной системы. В кн.: Болезни нервной системы. Руководство. В 2 т. Под. ред. акад. РАМН Н.Н. Яхно. М.: Медицина, 2005. С.460–570; Quvrier R.A., McLeod J.G., Pollard J.D. Peripheral neuropathy in childhood. Mac Keith press. Sydney, Australia. 1999.; Van den Bergh P.Y.K., Hadden R.D.M., Bouche P. et al. Chronic inflammatory demyelinating polyradiculoneuropathy. In: N.E. Gilhus, M.P. Barnes, M. Brainin (eds.). European Handbook of Neurological Management. Oxford: Blackwell Publishing Ltd, 2011. P. 333–342.; Николаев С.Г. Атлас по электромиографии. Иваново: ИПК «ПресСто», 2010.; Гехт Б.М., Касаткина Л.Ф., Самойлов М.И., Санадзе А.Г. Электромиография в диагностике нервно-; мышечных заболеваний. Таганрог, 1997.; Левин О.С. Полинейропатии. М.: МИА, 2005.; Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differentialdiagnosis of diabetic neuropathy. Curr Diab Rep 2009;9(6):423–31.; Azhary H., Farooq M.U., Bhanushali M. et al. Peripheral neuropathy: differential diagnosis and management. Am Fam Physician 2010;1;81(7):887–92.; Jann S., Bramerio M.A., Facchetti D., Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 2009;80(1):70–3.; Ayyar D.R., Sharma K.R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus. Curr Diab Rep 2004;4(6):409–12.; Jann S., Bramerio M.A., Beretta S. et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 2003;61(11): 1607–10.; Lozeron P., Nahum L., Lacroix C. et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 2002;249(5):569–75.; Dyck P.J., Norell J.E., Dyck P.J. Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain 2001;124(Pt 6):1197–207.; Dyck P.J., Windebank A.J. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25(4):477–91.; Pascoe M.K., Low P.A., Windebank A.J, Litchy W.J. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997;72(12):1123–32.; Amato A.A., Barohn R.J. Diabetic Lumbosacral Polyradiculoneuropathies. Curr Treat Options Neurol 2001;3(2):139–46.; Rotta F.T., Sussman A.T., Bradley W.G. et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173(2):129–39.; Krendel D.A., Costigan D.A., Hopkins L.C. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52(11):1053–61.; https://nmb.abvpress.ru/jour/article/view/100

  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20